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Abstract
Recently, the non-coding RNAs (ncRNAs) have been classified in different 
categories, and its importance in regulating different cellular processes has been 
unravelled. The long non-coding RNAs (lncRNAs) can interact with DNA, other 
RNAs and proteins, including epigenetic modifiers. Some lncRNAs are related to 
genomic imprinting and are associated with chromatin-modifying complexes that 
can regulate gene transcription. It is well established that cancer cells have different 
epigenetic alterations and some of these modifications are associated with lncRNAs. 
Studies of cancer-associated lncRNAs have defined its function in the process of 
tumorigenesis, its impact on cell proliferation, cellular signalling, angiogenesis and 
metastasis. Therefore, having a better knowledge of their role might contribute to a 
better understanding of the diseases. In this chapter, we will discuss about lncRNA 
classification and functions, epigenetic marks and how they can guide transcrip-
tion. Nevertheless, we will discuss how these mechanisms can interact and guide 
gene expression, as well as recently findings of dysregulation of lncRNAs in cancer.
Keywords: epigenetics, lncRNAs, DNA methylation, histone modifications, cancer
1. An overview
The patterns of gene expression of a cell are altered throughout its lifetime, 
and these changes occur as a response to different stimuli. For example, during 
the differentiation stage of an embryonic cell, a group of active genes dictates 
the cell fate, while after differentiation those genes are silenced since they are no 
longer needed for that task. In this manner, shifts in gene expression may occur 
within different mechanisms. However, the most important alterations occur 
in the epigenome level. The epigenome is dynamic, being constantly altered by 
different chemical modifications such as DNA methylation, histone modifica-
tions, nucleosome positioning and chromatin remodelling. Those changes make 
the DNA sequences more or less accessible to the transcriptional machinery, 
altering gene expression in a cell. The regulation of these mechanisms is complex 
and involves enzymes, proteins and RNA molecules. In the last years, it has been 
shown that long non-coding RNAs are also responsible for regulating transcription 
and they can do it in three different levels: pre-transcriptional, transcriptional 
and post-transcriptional. Besides these regulatory functions, they can also alter 
gene expression by altering the epigenome. Epigenomic alterations may alter gene 
expression and are related to the onset of many diseases and have been reported 
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to be crucial to cancer development. In cancer cells, tumour suppressor genes are 
silenced, and oncogenes are overexpressed, and these alterations can be driven by 
epigenetic modifications regulated by lncRNAs. In this chapter, we will discuss 
about lncRNAs and epigenetic marks. Nevertheless, we will approach how they can 
interact with each other to regulate gene expression and their role in cancer.
2. Long non-coding RNA
The discovery of ribonucleic acid (RNA) molecules that do not code for 
proteins has drastically altered our understanding of molecular biology. Until 
recent years, the central dogma of biology described the DNA as the source of 
information from which an encoded gene was transcribed into a RNA strand 
and after it would be translated into a protein. However, in the human genome, 
approximately 93% of the DNA can be transcribed into RNA, but only around 
2% of that would be protein-coding messenger RNA (mRNA). The remaining 
transcripts were therefore classified as transcriptional noise. With the rapid 
advance in molecular biology techniques, including large-scale sequencing, it 
is now known that many thousands of non-coding transcripts are encoded by 
the genome. These transcripts represent more than 70% of the genome, and 
they are transcribed into non-coding RNA (ncRNA) molecules. This knowledge 
opens up a completely new universe, and currently more than 40 types of 
non-coding RNAs have already been described. Among the most well-known 
ncRNAs are the transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), microRNAs 
(miRNAs) and, more recently, the long non-coding RNAs (lncRNAs), which are 
the focus of this chapter.
2.1 Characteristics of lncRNAs
The lncRNAs, as the name suggests, are long RNA transcripts, with more than 
200 nucleotides which are not translated into protein. The first long non-coding 
RNA was described in 1971, in a viroid plant pathogen; however, the first time 
a long non-coding RNA had its regulatory role described was only in the early 
1990s, when the scientific community discovered transcripts involved in epigenetic 
mechanisms. One of the first identified lncRNAs was H19 (imprinted maternally 
expressed transcript), firstly described in mouse [1]. Shortly after, X-inactive-
specific transcript (XIST) was suggested to be a functional lncRNA, with a struc-
tural role in the cell nucleus. lncRNAs present relatively low levels of evolutionary 
conservation and originated from genes that are usually shorter than protein coding 
genes, with fewer exons [2]. However, they present similar features with protein-
coding transcripts, as they are typically transcribed by RNA polymerase II and can 
be capped, polyadenylated and spliced [3].
lncRNAs can be transcribed from both mitochondrial and nuclear genomes, 
in sense and antisense directions. Also, strong evidence suggest that the 
 post-transcriptional cleavage of the lncRNAs might be the substrate to smaller 
RNAs, as they can act as precursors to smaller molecules such as miRNAs, piR-
NAs, siRNAs and others.
One of the main characteristics of lncRNAs is their ability to fold themselves 
into secondary or higher thermodynamically stable structures, which are highly 
conserved [4]. The longer the lncRNA, the higher is the probability of it to form 
those structures. Because lncRNAs have the capacity to bind through bonds, they 
are able to fold themselves into structures such as double-helix, hairpins, loops, 
pseudonodes and more. Due to these complex structures, they are able to bind to 
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more than one molecule at a time, regulating gene expression at different levels 
through RNA-protein, RNA-DNA and RNA-RNA complexes.
lncRNAs can be expressed in different cell compartments, and their function 
is directly related to their location. A substantial proportion of lncRNAs are exclu-
sively expressed in the nucleus. Nuclear lncRNAs often play a role in modulating 
gene expression by recruiting transcription factors, by remodelling or by modify-
ing the chromatin or by RNA-DNA triplex formation [5]. Other lncRNAs must 
be transported to the cytoplasm, where they may interfere in post-translational 
modification, participating in protein localization processes, mRNA translation 
and stability [6]. Not only that, lncRNAs may also be transported to distant regions 
through extracellular vesicles, such as exosomes and microvesicles; however, the 
mechanisms which regulate the expression of these circulating lncRNAs are still not 
well understood [7, 8].
2.2 The lncRNA classification
Because lncRNAs are a very diverse class of molecules, there is still a debate on 
which would be the best way to classify them into categories, as the classification 
can infer information regarding their localization, regulatory function, biological 
function and so on. The simplest method of lncRNA classification is related to their 
size [9, 10]: small lncRNA (200–950 nt), medium lncRNA (950–4800 nt) and large 
lncRNA (>4800 nt). According to this classification, most human lncRNAs fall into 
the small-lncRNA group (58%).
Another classification by the catalogue of human lncRNAs, made in 2012, 
defines five biotypes of lncRNAs according to the GENCODE (Figure 1):
Figure 1. 
lncRNA biotype classification. The image shows the lncRNA biotypes: antisense, lincRNA, sense overlapping 
and sense intronic. Blue squares represent gene coding exons, and green squares represent lncRNA exons; 
directions of transcription are indicated by arrows.
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1. Antisense: located on the opposite strand from protein-coding genes, con-
taining an intersection with some exons or introns or published evidence of 
antisense gene regulation
2. Long intergenic non-coding RNA (lincRNA): transcripts originated from 
intergenic loci; that is, located between two protein-coding genes
3. Sense overlapping: transcripts containing ‘protein-coding gene sequences in 
their introns’, located in the same strand as them and that do not overlap with 
any exon
4. Sense intronic: located within introns of a protein-coding gene and with no 
intersection with exons
5. Processed transcripts: locus where all transcripts have no open reading frame 
(ORF) and do not fit in any of the above biotypes, due to their complex 
structure
It is important to note that even though this classification is widely used, 
additional biotypes of lncRNAs are also described in GENCODE, such as macro 
lncRNAs, pseudogenes, 3 prime overlapping ncRNA and bidirectional promoter 
lncRNA, among others. Alternatively, lncRNAs can be categorized according to the 
molecular mechanisms that may be involved in their functions into five archetypes:
1. Signal archetype: acts as a molecular signal or indicator of transcriptional 
activity
2. Decoy archetype: binds and captures other molecules, such as proteins and other 
regulatory RNAs, inhibiting its function
3. Guide archetype: binds and recruits ribonucleoprotein complexes to specific 
targets
4. Scaffold archetype: plays a structural role as a platform upon which other 
molecules can bind simultaneously, assembling a complex
5. Enhancer archetype: controls higher-order chromosomal looping
Nevertheless, they can also be classified based on the region of the DNA 
sequence impacted by the lncRNA. lncRNAs can influence a neighbouring gene on 
the same allele from which it is transcribed (cis) or in further genomic region and 
other chromosomes (trans):
1. Cis-lncRNAs: lncRNAs regulating the expression of genes in close genomic 
proximity. They may be transcribed from promoter regions and may interfere 
in the transcription activity of neighbouring genes. They may act by recruiting 
transcription factors, inducing chromatin remodelling or forming DNA-RNA 
triplex structure.
One of the most well-known examples of cis-acting lncRNA is XIST. In mam-
mals, the females have two copies of the X chromosome (XX), while the males have 
only one (XY). This unbalance could result in a variety of problems associated with 
the expression of genes from chromosome X. However, the lncRNA X-inactive-
specific transcript (XIST) is expressed from the X-inactivation centre (XIC) locus 
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and acts in cis along the whole chromosome from which it is transcribed, resulting 
in this chromosome silencing (Figure 2A).
2. Trans-lncRNAs: lncRNAs may also function in trans-mode by influencing 
distant gene loci. In such case, they may also act as chromatin modification 
complexes, as well as affect transcription by binding to transcription elonga-
tion factors or to RNA polymerases.
Another well-studied lncRNA, HOX transcript antisense RNA (HOTAIR), also 
recruits the polycomb repressive complex 2 (PRC2) to inactivate gene expression. 
However, in this case, HOTAIR is transcribed from the HoxC locus on chromosome 12 
and represses the HoxD locus on chromosome 2, therefore acting in trans (Figure 2B).
2.3 Gene expression regulation mediated by lncRNAs
Long non-coding RNAs are functionally very diverse and are involved in numer-
ous biological roles, such as imprinting, epigenetic regulation, apoptosis and cell 
cycle control, transcriptional and translational regulation, splicing, cell development 
and differentiation and ageing. They have been described in almost every stage 
of gene regulation: pre-transcriptionally, guiding proteins to specific areas of the 
genome; as decoys, keeping proteins away from chromatin; by epigenetic alterations, 
by histone modifications or DNA methylation [3]; transcriptionally, modulating the 
transcriptional process; and post-transcriptionally, by RNA-RNA interactions.
2.3.1 Pre-transcriptional regulation
It is well understood that, in eukaryotic cells, the DNA is packaged in the chromatin 
and the availability of those structures to the transcriptional machinery has a strong 
influence in the gene expression, as the transcriptional factors must have access to 
the chromatin in order to transcribe the encoded gene. The lncRNAs can regulate this 
expression in the nucleus by associating and recruiting chromatin-remodelling factors. 
The examples of XIST and HOTAIR mentioned above illustrate this pre-transcription 
regulation, as in both examples, XIST and HOTAIR recruit the PRC2 to interact and 
repress the expression of genes through the K27 trimethylation in H3 histones [11].
Figure 2. 
Cis and trans regulation of gene expression by lncRNAs. (A) Inactivation of the X chromosome by the lncRNA 
XIST, cis-acting in the same chromosome; (B) lncRNA HOTAIR is transcribed in chromosome 12 and acts in 




The lncRNAs located in the cell nucleus can participate in the transcription 
regulation and are divided into two different categories, according to its func-
tion: promoter-associated lncRNAs (plncRNAs) and enhancer-like lncRNAs 
(elncRNAs).
The plncRNAs may act as inhibitor or promoter of gene expression. For exam-
ple, the dihydrofolate reductase (DHFR) gene contains two promoters, with the 
downstream major promoter being responsible for 99% of the RNA transcription. 
However, the transcription from the upstream minor promoter generates a lncRNA 
transcript that interacts both with the major promoter and the transcription factor 
IIB (TFIIB), forming a triplex structure between DNA and RNA, which inhibits 
the binding of TFIIB with the major promoter causing the inhibition of DHFR gene 
expression [12].
Another example is the lncRNA Evf-2, which acts on cis as a distal-less homeo-
box 2 (DLX2) protein coactivator, creating a stable complex that activates the 
transcription of the adjacent locus distal-less homeobox 5/6 (DLx5/6) [13].
2.3.3 Post-transcription regulation
lncRNAs may act upon the post-transcription regulation in different ways. In 
the nucleus or in the cytoplasm, they can alter the mRNA stability, splicing or even 
cellular compartmental distribution. The zinc finger E-box binding homeobox 2 
(ZEB2) gene is transcribed in the DNA sense strand of chromosome 2. On its oppo-
site strand, the lncRNA ZEB2 natural antisense transcript (ZEB2NAT) can mask the 
splicing site of an intron in the 5’UTR region of the ZEB2 mRNA by complementary 
binding. This interaction avoids the spliceosome attachment, allowing the expres-
sion of the ZEB2 protein [14].
In another case, in the cytoplasm, lncRNAs can also act as miRNA ‘sponges’, 
when the mRNA and the lncRNA have similar miRNA binding sites. Therefore, 
when the lncRNA binds to the miRNA, the miRNA is no longer available for 
mRNA attachment, increasing the concentration of the mRNA in the cytoplasm. 
The phosphatase and tensin homolog (PTEN) gene and the lncRNA phosphatase 
and tensin homolog pseudogene-1 (PTEN1) illustrate this action mode. They both 
share similar nucleotide sequences. The miRNA families miR-17, miR-21, miR-214, 
miR-19 and miR-26 contain in their 3’UTR region a perfect match binding sequence 
to PTEN1. Therefore, the lncRNA acts as bait and sequesters the miRNAs that would 
otherwise bind to PTEN mRNA [15].
3. Epigenetic regulatory functions of lncRNAs
As mentioned above, lncRNAs can interact with epigenetic mechanisms 
altering gene expression. But what are those mechanisms? Epigenetics refers to 
chemical modifications of the chromatin, without alterations in the nucleotide 
sequence, which are transmitted throughout mitosis and play a key role in gene 
expression regulation and genomic stability. Among epigenetic mechanisms are 
DNA methylation, post-translational histone modifications, nucleosome posi-
tioning and chromatin accessibility. All these epigenetic marks interact with each 
other in a dynamic way altering patterns of gene expression along embryogenesis, 
throughout lifetime by environmental stimulus and in the transition health-
disease stage.
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3.1 Chromatin structure and epigenetic marks
Different states of chromatin organization allow different transcriptional factors 
to bind to DNA and regulate gene expression. This interaction between transcrip-
tional factors and DNA is only possible due to a chromatin open state, known as 
euchromatin. The inactive form of chromatin is called heterochromatin and is 
characterized by epigenetic marks that make this structure highly condensed. The 
negatively charged phosphate backbone of DNA is wrapped around an octamer of 
histone proteins, forming the nucleosome. The histone octamer is made out of a pair 
of each histone protein H2A, H2B, H3 and H4, and these structures are linked by 
the histone H1 protein. The epigenetic marks are written by enzymes that can add 
methyl groups to cytosine in the genomic DNA (DNA methyltransferases; DNMTs) 
and acetyl and methyl groups to amino acid residues of histone proteins (histones 
acetylases and methylases; HATs and HMTs, respectively). These marks can be 
interpreted by proteins that bind to methylated DNA, such as methyl CpG-binding 
domain (MBDs) proteins, and to modified histones, as proteins containing chromo- 
and bromodomains. Epigenetic marks can also be further erased by enzymes, such as 
histone deacetylases and demethylases (HDACs and HDMs), respectively, as well as 
the family of ten-eleven translocation (TETs), which oxidases the 5-methylcytosine.
3.1.1 DNA methylation
DNA methylation is the process in which a methyl group is added to the fifth car-
bon of a cytosine resulting in 5-methylcytosine (5mC). The methyl group is donated 
from S-adenosyl methionine (SAM), and this reaction is catalyzed by DNMT 
enzymes. In mammals, the methylation process usually occurs in the CpG dinucleo-
tide context, but is not limited to this condition. There are five types of DNMTs 
in mammals: DNMT1, DNMT3A, DNMT3B, DNMT2 and DNMT3L. During the 
replication process of a cell, DNMT1 recognizes 5mC in the hemimethylated DNA 
and is responsible for the reestablishment of the methylation patterns in the daugh-
ter strand, which makes the epigenetic marks heritable during cell division. For this 
reason, DNMT1 can be called as a maintenance DNA methyltransferase. DNMT3A 
and DNMT3B do not prefer hemimethylated DNA, being able to establish de novo 
(new) methylation patterns especially during cell differentiation in embryogenesis. 
DNMT3L does not have catalytic activity but can act as a cofactor of DNMT3A to 
improve its affinity to DNA and further improve the methylation process. Despite 
the fact that DNMT2 has no strong catalytic activity to DNA, it was recently showed 
that this enzyme is capable of adding methyl groups to tRNA.
The methylation pattern of the human genome is said to be bimodal; in other 
words, that means that some regions have a low methylation level, as transcription 
start sites (TSS) with high content of CpGs and imprinting control regions (ICR), 
although the other CpG sites in the genome are kept methylated. The CpG islands 
(CGI) are known as CpG-rich regions within the DNA sequence, and they can be 
related with gene expression. For example, it is well established that TSS with high 
methylation of CGI are related with a long-term silencing. Methylation of promoter 
regions is associated with transcriptional repression, while the non-methylated pro-
moters are associated with active transcription. Methylated DNA acts as a physical bar-
rier for transcription factors and, additionally, recruits MBDs that also act as repression 
complexes. However, methylation at the gene body is related with active transcribed 
genes; for example, when the methyl-CpG binding protein 2 (MeCP2) identifies meth-
ylated exons, it may regulate alternative splicing. Furthermore, transposable elements 
can also be silenced by DNA methylation, contributing to genome stability.
Non-Coding RNAs
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Demethylation of the genome is an important process during the pre-implanta-
tion phase and germ cell development. The enzymes responsible for this multistep 
process are the TET proteins capable of oxidizing 5mC, leading to the loss of DNA 
methylation. DNMTs and TETs can dynamically regulate transcription repression 
and activation across the genome. DNA methylation is a stable mark for gene silenc-
ing, but is not the only one.
Interactions between DNA methylation marks and lncRNAs may happen in 
order to control gene expression. As an example, one of TET proteins, TET2, has 
been shown to negatively regulate the expression of the lncRNA antisense ncRNA 
in the INK4 locus (ANRIL) through its binding affinity with the lncRNA promoter, 
regulating not only its expression but the expression of its downstream genes as 
well. In addition, another negative correlation has been observed between TET2 
and the methylation pattern of the lncRNA maternally expressed gene 3 (MEG3) 
promoter. This is particularly interesting considering that MEG3 promoter meth-
ylation has been associated with poor survival in myeloid malignancies and the 
same trend has been observed in breast, cervical, colon, liver, lung and prostate 
cancer cell lines [16, 17]. As mentioned previously, lncRNA XIST is responsible 
for X-chromosome inactivation. However, the active X chromosome expresses the 
lncRNA TSIX, antisense to XIST through its 5′ end, that interacts with PRC2 and 
enhances DNA hypermethylation through DNMT3A, resulting in XIST silencing. 
Conversely, neither PRC2 nor DNMT3A is essential for XIST expression, which 
implies that more than one pathway acts in the TSIX/XIST regulation complex. 
Another lncRNA that interferes in DNA methylation is H19 that was discovered 
to interact with methyl-CpG-binding domain protein 1 (MBD1), which recruits 
different enzymes that are related to gene silencing. Besides that, it was also identi-
fied to bind with S-adenosyl homocysteine hydrolase (SAHH) and hydrolysis 
S-adenosyl homocysteine (SAH) and block DNA methylation by DNMT3B [18, 19]. 
It is also known that H19 is part of an imprinted gene network that is only expressed 
from maternal allele. Interestingly, the silencing of the paternal allele is due to CpG 
methylation of the H19 promoter. Genomic imprinting is an epigenetic mechanism 
that restricts the expression of a gene to only one allele, either maternal or paternal. 
The lncRNA Nespas belongs to the Gnas imprinted cluster. Nespas transcription 
through the paternal allele is inversely correlated with Nesp. Nesp promoter in this 
context is encountered methylated due to Nespas ability to recruit KDM1B (histone 
demethylase 1B) and therefore demethylate lysine 4 of histone 3 [20].
3.1.2 Histone modifications and chromatin remodellers
Other epigenetic marks are the post-translational modifications of histone 
proteins. Histone modifications are more plastic and can lead to repression and 
activation of transcription, depending on the modification and the residue to be 
modified. The main targets of modifications are the amino acids located in the 
N-terminal portion of histone tails that shape the nucleosome. Lysine is the amino 
acid that can accommodate more combinations of modifications; however, other 
histone residues can also be modified, such as arginine, serine, threonine and 
tyrosine. Some of the most studied modifications are methylation and acetylation, 
but modifications as phosphorylation, ubiquitination and ADP-ribosylation also 
occur. Histone acetylation is a mark related to active gene expression. The acetyl 
group neutralizes the positive charge of histones, and due to this new charge, since 
the DNA has a negative backbone, the DNA-histone interactions are lowered, and 
this repulsion makes this loosen structure more accessible to the transcription 
machinery. An example of acetylation controlling gene expression is the acetyla-
tion of histone H3: high-acetylated genome regions are related to highly expressed 
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genes, while low acetylation is present in silenced genomic regions. While histone 
acetylation profiles can indicate active or repressive regions of the genome, the 
effect of histone methylation depends on the residue where it occurs and their 
degree of methylation, whether once, twice or three times methylated (mono, di 
or tri, respectively). Just like DNA methylation, the methyl group added in histone 
residues is donated from SAM; however, this reaction is catalyzed by HMTs. The 
most commonly methylated histones are H3 and H4, and some marks are already 
related with different states of chromatin accessibility. For example, trimethylation 
of lysine 9 in histone H3 (H3K9me3) and trimethylation of lysine 20 in histone 
H4 (H4K20me3) are associated with inactive regions of the genome, while mono-
methylation of lysine 9 in histone H3 (H3K9me1) and mono-methylation of lysine 
20 in histone H4 (H4K20me1) are related with active genome regions. The mecha-
nism that erases those marks are guided by different enzymes, including HDACs 
and HDMs, responsible for removing, respectively, acetyl and methyl groups from 
the histones. The process of histone modification and its cooperation with DNA 
methylation makes the epigenome very dynamic and plastic during different stages 
of cell development.
The nucleosome occupancy in the chromatin and the changes that may occur 
in this structure are important to guide gene expression. Chromatin remodellers 
use the energy of adenosine triphosphate (ATP) hydrolysis to alter the nucleosome 
position. These remodellers are multi-protein complexes that can modulate nucleo-
some occupancy with the help of transcriptional cofactors, pioneer factors and non-
coding RNAs. The coordinated mechanism of nucleosome modifications and DNA 
accessibility can occur in at least four ways: (1) sliding of the nucleosome: sup-
ported by imitation switch (ISWI), chromodomain-helicase-DNA (CHD) binding 
and chromatin remodeller families; it is characterized by the transfer of the nucleo-
some to a new position but without changing its chromatin region; (2) nucleosome 
ejection: mediated by imitation switch/sucrose non-fermentable (ISWI/SNF) 
remodeller family; the nucleosome is taken out of its position, and the DNA in that 
area becomes accessible; (3) nucleosome-selective dimer removal: mediated by 
SWI/SNF family, destabilizes the nucleosome since it leaves only two tetrameters 
within the nucleosome; (4) nucleosome histone replacement: histone variants such 
as H2A is replaced by H2A.Z, mediated by the inositol (INO)-requiring family. 
Therefore, all those modifications are important to maintain the dynamic regula-
tion of gene expression. The histone-modifying complexes (PRC1/PRC2) and the 
trithorax group/mixed-lineage leukaemia (MLL) protein complexes (TrxG/MLL) 
are important players on the control of chromatin structure and, therefore, are 
important regulators of gene activity. PRC2 promotes the methylation of histone H3 
at lysine 27 (H3K27me3), inhibiting gene activity, while on the other hand, TrxG/
MLL stimulates the methylation of histone H3 at lysine 4 (H3K4me3), triggering 
gene expression.
In the literature, many lncRNAs have been reported to alter gene expression 
through histone modifications and chromatin remodelling. lncRNAs can interact 
with chromatin remodellers in order to promote or repress gene expression according 
to its genomic regions. For instance, they can interact with multiple regulatory com-
plexes at the same time and bind with different enzymes that can change chromatin 
marks, such as DNA methylation, histone modifications and nucleosome modifica-
tions. lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) 
can act as a molecular scaffold, and it is related to both gene silencing and gene 
activation. The lncRNA can bind to PRC2 complex, resulting in the methylation 
of histone H3 in lysine 27 (H3K27), which is a repression mark of gene expression. 
In other context, it can interact with nuclear speckles, structures that are thought 
to be associated with splicing and processing of pre-mRNA, coordinating gene 
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transcription and regulating splicing of mRNA [21]. The elncRNA HOTTIP (HOXA 
distal transcript antisense RNA) is transcribed from the 5′ tip of the homeobox A 
(HOXA) locus. HOTTIP binds with the WD repeat-containing protein 5 (WDR5) 
and recruits the methyltransferase MLL complex driving the histone H3 lysine 4 
trimethylation (H3K4me3) and coordinating the transcription of several genes from 
HOX cluster [22]. In addition, the lncRNA Foxf1 adjacent non-coding developmental 
regulatory RNA (FENDRR) also recruits silencing complexes such as PRC2, to guide 
then to regions that will be silenced. However, FENDRR also interacts with the TrxG/
MLL complex at a specific set of promoters, suggesting that there is a fine balance 
between FENDRR/PRC2 and FENDRR/MLL gene regulation [23, 24]. lncRNAs 
urothelial cancer associated 1 (UCA1), highly upregulated in liver cancer (HULC) 
and PVT1 lncRNAs can interact with the histone methyltransferase complex PRC2 
promoting trimethylation of lysine 27 on histone H3, silencing gene expression 
in gallbladder cancer, colorectal carcinoma and gastric cancer, respectively. Some 
lncRNAs can also interact with the chromatin remodellers of the ISWI/SNF family in 
order to recruit this complex to genome regions to activate transcription; an example 
is the lncRNA transcription factor 7 (TCF7) in hepatocarcinoma cells. Other 
lncRNAs, such as lncRNA nuclear enriched transcript 1 (NEAT1) may also interact 
with the SWI/SNF complex; however, the specific mechanisms and function are still 
unclear. Together, these recent findings of how lncRNAs regulate gene expression 
through epigenetic marks still need to be more elucidated. Accumulating evidence 
over the last years indicates that lncRNAs play a major role in regulating gene expres-
sion through epigenetic marks. However, the comprehension of these mechanisms 
still needs to be more elucidated. Nevertheless, based on the topics discussed, the 
main interactions between lncRNAs and the epigenetic machinery are illustrated 
with one example of each in Figure 3.
3.2 Epigenetic regulation, lncRNAs and cancer
Human cancers are complex diseases involving multiple genetic and epigenetic 
alterations, while only part of the DNA mutations corresponds to the malignant 
phenotype; recent research has demonstrated the importance of the epigenetic 
alterations in the development of tumours. The switch from silenced genes to 
actively transcribed genes and vice versa is regulated by complex mechanisms 
and alterations within the cell machinery. Cancer cells present variations within 
DNA methylation patterns, such as global hypomethylation profile and CpG island 
hypermethylation in promoter regions. Due to these modifications, the cancer cell 
Figure 3. 
lncRNAs as epigenetic regulators. The image shows the lncRNA H19 that binds with SAHH and inhibits SAH 
hydrolysis blocking DNA methylation by DNMT3B; lncRNA HOTAIR silencing expression of target by binding 
with PRC2 and LSD1 promoting H3K27me3 and demethylation of H3K4me2; and TCF7 binding with the 
SWI/SNF complex, promoting the activation of gene expression by chromatin remodelling.
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genome presents chromosomal instability, loss of genomic imprinting and changes 
in gene expression, both for protein coding and regulatory non-coding RNAs.
With the development of high-throughput sequencing, a number of stud-
ies have provided an ever-expanding survey on genetic aberrations in cancer. 
However, these abnormalities also affect lncRNAs, disrupting their functions 
and consequently leading to deregulation of their targets. Some of the recurring 
molecular mechanisms that govern how lncRNAs regulate cellular processes were 
highlighted earlier in this chapter. Most well-characterized lncRNAs to date show a 
functional role in gene expression regulation, typically transcriptional rather than 
post-transcriptional regulation. With advances in cancer transcriptome profiling 
and accumulated evidence supporting lncRNA functions, a number of differen-
tially expressed lncRNAs have been associated with several types of cancers, which 
simultaneously acquire one or more dynamic modifications within their structures. 
Here, a few lncRNAs that have already been reported to participate in cancer 
progression will be mentioned, as detailed below.
XIST is one of the best-studied lncRNAs, and as such, it has been searched 
for and found in many different human neoplasias. Its expression can be either 
upregulated or downregulated, acting as an oncogene or as a tumour suppressor 
in multiple types of cancer. Overexpression of XIST is associated with advanced 
tumour stage, lymph node or distant metastasis and overall poor prognosis in 
human cancers. In breast cancer, XIST acts as a tumour suppressor by positively 
regulating the expression of non-X-chromosome gene PH domain and leucine-rich 
repeat protein phosphatase 1 (PHLPP1), which in turn catalyses dephosphorylation 
of protein kinase B (AKT) [25]. In non-small-cell lung cancer (NSCLC), naso-
pharyngeal and hepatocellular carcinoma, osteosarcoma and gastric, colorectal, 
pancreatic and bladder cancer, its expression is upregulated, acting as an oncogene 
and promoting cell proliferation and migration. XIST was also described acting as a 
sponge for miR-186-5p, and its knockdown suppresses multiplication and invasion 
in NSCLC.
MALAT1 is another well-studied lncRNA. Its high expression has been associ-
ated with gastric cancer, melanoma, breast cancer tumour and metastatic progres-
sion. MALAT1 also functions in key spots of cancer development process, since it 
regulates transcription of oncogenic targets and regulates itself interacting with 
transcription factors [26]. This lncRNA can mediate transcription factors binding 
to target gene promoters or can act as a sponge to sequester miRNAs, controlling 
miRNA suppressor effects on oncogenic targets. On the other hand, epigenetic 
modifications occurring at histone level, for instance, demethylation of histone 
H3 in lysine 9 position (H3K9) by a demethylase that binds to the MALAT1 pro-
moter, may result in MALAT1 lncRNA overexpression [27, 28].
HOTAIR is a lncRNA involved in gene silencing by interaction with two 
chromatin-modifying complexes and plays numerous roles in cancer development. 
Altered expression of HOTAIR is found in many types of cancers [29], promoting 
metastasis and tumour invasiveness through epigenetic gene silencing. Cancer stem 
cells from breast, oral and colon carcinomas express high levels of HOTAIR associ-
ated with increased stemness and metastatic potential [30]. High levels of HOTAIR 
correlating with metastasis and poor prognosis have been found in lung cancer [31], 
hepatocellular carcinoma [32], breast cancer [29], gastric cancer [33], colorectal 
cancer [34], cervical cancer [35], ovarian cancer, head and neck carcinoma and 
oesophageal squamous cell carcinoma. Just recently, elevated HOTAIR expres-
sion was also identified in adrenocortical carcinoma, and it was demonstrated to 
induce cell proliferation. In addition, another recent study showed the potential of 
HOTAIR to promote osteosarcoma development. Evidence supporting HOTAIR’s 
role in mediating drug resistance has emerged from an investigation with different 
Non-Coding RNAs
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types of cancer. HOTAIR overexpression was found in samples from drug-resistant 
patients with NSCLC. Similar results demonstrated HOTAIR’s potential to promote 
resistance to cisplatin or other types of chemotherapy drugs. Those studies have 
been conducted with hepatocellular carcinoma, breast cancer, gastric cancer, 
colorectal cancer, cervical cancer and ovarian cancer [36–40].
The lncRNA H19 has been well-studied in cancer. Aberrant expression of H19 is 
observed in numerous solid tumours, including hepatocellular and bladder cancer. 
Functional data on H19 points in several directions, and it has been linked to both 
oncogenic and tumour suppressive qualities. For example, there is evidence for its 
direct activation by cMYC as well as its downregulation by p53 during prolonged 
cell proliferation. The siRNA knockdown of H19 impairs cell growth and clonoge-
nicity in lung cancer cell lines in vitro and decreased xenograft tumour growth of 
Hep3B hepatocellular carcinoma cells in vivo [41, 42].
DNMT1-associated lncRNA (DACOR1) was described to be repressed in colon 
cancer. The lncRNA was directly associated with demethylation of CpG sites by 
guiding DNMT1 methylation patterns across the genome at thousands of different 
CpG sites [43].
The long non-coding RNA PTENP1 is a well-known tumour suppressor gene. 
Studies have shown that PTENP1 increased PTEN protein levels by competing 
for a set of PTEN-targeting miRNAs, which downregulate PTEN independent of 
its protein-coding function. In colon cancer, the loss of focal copy number at the 
lncRNA Associated epigenetic marks Described in Ref.
XIST Histone modification, chromatin 
remodelling
Gastric, oesophageal [21, 51, 52]
MALAT1/a/NEA Histone modification Breast, lung [53–56]
HOTAIR Chromatin remodelling/histone 
modification
Breast, pancreas [36–40]
H19 DNA hypermethylation Gastric [41, 42, 57]
HULC Chromatin remodelling Hepato-, colorectal 
carcinoma
[58, 59]
GCLnc1 Histone modification Gastric cancer [60]
DACOR1 DNA methylation Colon cancer [38]
FENDRR Histone modification Gastric, lung cancers [61]
UCA1 Chromatin remodelling Colorectal cancer [62, 63]
TCF7 Chromatin remodelling Liver cancer [64]
TP53TG1 CGI hypermethylation Colorectal, gastric 
cancers
[65]
ANRIL Chromatin remodelling Prostate cancer, 
leukaemia
[66]
MEG3 Promoter/imprinting control 
hypermethylation
Brain tumour [67]
GAS5 Histone modification Breast cancer [68]
NEAT1 Chromatin remodelling Cervical renal, lung [69–73]
PVT1 Histone modification Renal, gastric [70–75]
The table shows some examples of lncRNAs, with their respective epigenetic mark and in what cancer they were 
described.
Table 1. 
lncRNAs altered in cancer and associated epigenetic marks.
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PTENP1 locus was associated with the downregulation of PTEN expression in colon 
cancer patients. A similar relationship was shown between the oncogene KRAS and 
its pseudogene KRAS1P in colon cancer [15, 44]. PTENP1 has been downregulated 
or suppressed in several cancers, such as GC, hepatocellular carcinoma (HCC), 
renal cell carcinoma, head and neck squamous cell carcinoma (HNSCC), mela-
noma, endometrial cancer and oral squamous cell carcinoma (OSCC) [45–50].
Besides the alterations mentioned above, some lncRNAs were also related to 
specific epigenetic marks in cancer. However, not all of these marks were well 
elucidated in all types of cancer. Table 1 shows some lncRNAs that were described 
in different cancer types and what epigenetic mark they can regulate.
4. Conclusions
Gene expression can be regulated by different mechanisms; however, epigenetic 
alterations have a major effect in this process. We discussed the different ways 
by which lncRNAs may interact with epigenetic marks to guide gene expression. 
Furthermore, the complete panorama of how these interactions work remains 
unclear, as we are only beginning to understand the connections between lncRNAs 
and the epigenome. Since accumulating evidence shows that lncRNAs can regulate 
gene expression in cancer cells, understanding the mechanisms by which these 
molecules work on it is essential for comprehending cancer development and 
progression, in order to develop better diagnostic tools and treatments. There is still 
a long way to go on this road, until we can finally elucidate the rules that guide these 
interactions as well as the functional implications of these associations.
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